In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and Director Steve Saviuk about an update on the new drug Sabizabulin for the treatment of COVID-19 patients. Being accepted for review by Health Canada, Steve explains how Sabizabulin showed a 51.6% reduction in deaths in hospitalized adult patients with moderate to severe COVID-19.
Having recently reported their best quarter ever, Saviuk discusses Valeo’s record fourth quarter and fiscal year 2022 revenues which were up 274% and 105%, respectively. Steve goes on to provide an update on Valeo’s portfolio of high-growth potential respiratory/allergy, ophthalmology, and hospital specialty products that are driving revenues.
To access the full InvestorIntel interview, click here
Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.
To know more about Valeo Pharma Inc., click here
Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at firstname.lastname@example.org.
Leave a Reply